Avadel Pharmaceuticals plc
AVDL
$14.20
$0.201.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 132.35% | 252.64% | 504.79% | 1,523.50% | 6,260.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 132.35% | 252.64% | 504.79% | 1,523.50% | 6,260.23% |
| Cost of Revenue | 347.46% | 716.39% | 1,705.79% | 7,192.81% | 14,122.22% |
| Gross Profit | 120.11% | 231.83% | 467.32% | 1,419.71% | 6,066.37% |
| SG&A Expenses | 1.55% | 1.22% | 19.34% | 39.52% | 72.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.83% | 12.11% | 27.56% | 39.74% | 62.18% |
| Operating Income | 102.29% | 85.72% | 69.24% | 53.00% | 16.34% |
| Income Before Tax | 94.52% | 82.97% | 69.47% | 54.16% | 25.50% |
| Income Tax Expenses | -584.78% | -252.91% | 50.50% | -35.44% | -27.46% |
| Earnings from Continuing Operations | 97.25% | 83.16% | 69.53% | 54.34% | 25.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 97.25% | 83.16% | 69.53% | 54.34% | 25.62% |
| EBIT | 102.29% | 85.72% | 69.24% | 53.00% | 16.34% |
| EBITDA | 106.05% | 87.71% | 70.71% | 54.00% | 16.51% |
| EPS Basic | 97.38% | 85.24% | 74.46% | 63.49% | 44.15% |
| Normalized Basic EPS | 94.16% | 82.53% | 70.90% | 60.17% | 39.12% |
| EPS Diluted | 97.16% | 85.14% | 74.29% | 63.44% | 44.01% |
| Normalized Diluted EPS | 94.02% | 82.53% | 70.90% | 60.17% | 39.12% |
| Average Basic Shares Outstanding | 5.15% | 10.69% | 18.76% | 27.74% | 39.26% |
| Average Diluted Shares Outstanding | 5.79% | 10.69% | 18.76% | 27.74% | 39.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |